Skip to content

ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)

ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06371820
Acronym
ESPRESSO
Enrollment
13000000
Registered
2024-04-17
Start date
1965-01-01
Completion date
2043-05-17
Last updated
2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Diseases

Keywords

cohort, gallbladder, gut, liver, pancreas, population-based, colon, pathology, endoscopy, celiac, inflammatory bowel disease, colitis, esophagus

Brief summary

The ESPRESSO study is a collection of data from all computerised gastrointestinal histopathology reports in Sweden. This allows us to study risk factors for gastrointestinal disease, as well as the prognosis of gastrointestinal disease. A review of the study has been published here: https://pubmed.ncbi.nlm.nih.gov/30679926/

Detailed description

The ESPRESSO study constitutes a novel approach to examine the etiology and prognosis of gastrointestinal disease in which histopathology plays a prominent role. Between 2015 and 2017, all pathology departments (n=28) in Sweden were contacted and asked to procure histopathology record data from the gastrointestinal tract (pharynx to anus), liver, gallbladder, and pancreas. For each individual, local histopathology IT personnel retrieved data on personal identity number, date of histopathology, topography (where the biopsy is taken), morphology (biopsy appearance), and where available free text. In total, between 1965 and 2017, histopathology record data were available in 2.1 million unique individuals, but the number of data entries was 6.1 million because more than one biopsy was performed in many of the study participants. Index individuals with histopathology data were matched with up to five controls from the general population. The investigators also identified all first-degree relatives (parents, children, full siblings), and the index individual's first spouse. The total study population consisted of 13.0 million individuals. Data from all the study participants have been linked to Swedish National Healthcare Registers allowing research not only on such aspects as fetal and perinatal conditions and the risk of future gastrointestinal disease but also on the risk of comorbidity and complications (including cancer and death). Furthermore, the ESPRESSO database allows researchers and practitioners to identify diagnoses and disease phenotypes not currently indexed in national registers (including disease precursors). The ESPRESSO database increases the sensitivity and specificity of already-recorded diseases in the national health registers. This paper is an overview of the ESPRESSO database.

Interventions

OTHERESPRESSO [The study has no intervention]

This study has no interventions.

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 110 Years

Inclusion criteria

* Any person with a computerised histopathology record from the gastrointestinal tract including the liver, gallbladder and the pancreas. * Matched controls to any person with the above histopathology record. * Spouses and first-degree relatives to any of the above.

Exclusion criteria

-None (this is a registry-based study)

Design outcomes

Primary

MeasureTime frameDescription
Incident Mortality [especially rates]Currently up until 2022Record of death in the Swedish Cause of Death Register. Please note: Different sub-projects will have different primary outcomes.

Secondary

MeasureTime frameDescription
Incident CancerCurrently up until 2022ICD (international classification of diseases) code in the Swedish nationwide cancer register.
Incident Cardiovascular diseaseCurrently up until 2022ICD (international classification of diseases) code in the Swedish nationwide Patient Register, and where appropriate also the Cause of Death Register
Incident Neurological diseaseCurrently up until 2022ICD (international classification of diseases) code in the Swedish nationwide Patient Register, and where appropriate also the Cause of Death Register
Incident Autoimmune diseasesCurrently up until 2022ICD (international classification of diseases) code in the Swedish nationwide Patient Register, and where appropriate also the Cause of Death Register

Other

MeasureTime frameDescription
Please note that the recorded outcomes above are examples. Other outcomes may also be studied.Currently up until 2022ICD codes as above

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026